Literature DB >> 34467896

Distinct roles of miR-34 family members on suppression of lung squamous cell carcinoma.

Dangze Sun1, Yao Wu2, Shanshan Zhang1, Yaxuan Han1, Jinglong Shen1, Wenhao Zheng1, Lin Wei1, Yugang Liu1, Leipeng Ren1, Zhenning Gu1, You Liu3, Shuhui Liu4, Chao Ding5.   

Abstract

miR-34, whose mimic was used on phase I clinical trial, has been extensively reported since its dysfunction in various cancers including non-small-cell lung cancer (NSCLC). However, the roles of miR-34 family members in the progression of lung squamous carcinoma (SCC) in patients who have occupational-exposure experience are unclear yet. Here, we comprehensively investigated the expression levels of miR-34 family members in SCC patients and compared the roles of them in SCC in vitro and vivo. The results showed that the average levels of miR-34a and miR-34b/c were decreased in patients. The analysis of miR-34a to miR-34b/c levels in patients graded different stages or metastases or recurrence showed that miR-34b/c was reduced earlier and more significantly than miR-34a. In vitro assays demonstrated that both miR-34a and miR-34b/c inhibits SCC cells proliferation, migration and invasion via Notch1 pathway, while miR-34b/c effects more than miR-34a does. As miR-34a was significantly decreased in cancer recurrence, the further analysis of relationship between miR-34a and stem cell adhesion molecular CD44 showed that miR-34a was significantly correlated with CD44 levels in patients. Knockdown of CD44 significantly blocked miR-34a mediated inhibition of cell migration and invasion. Treating the purified CD44hi cells with miR-34 overexpression lentivirus inhibited the tumor outgrowth. By contrast, anti-miR-34 facilitated tumor development of CD44low cells. Our study showed that miR-34 family members are negative regulator for SCC development, even though the inhibition is mediated by multiple and complicated signal pathways, which provides theoretical basis for SCC treatment and a biomarker candidate for SCC prognosis.
Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Cell growth; Lung squamous cell cancer; Metastasis; MiR-34a; MiR-34b/c

Mesh:

Substances:

Year:  2021        PMID: 34467896     DOI: 10.1016/j.biopha.2021.111967

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  6 in total

Review 1.  Lung Cancer Stem Cell Markers as Therapeutic Targets: An Update on Signaling Pathways and Therapies.

Authors:  Yue Zheng; Laduona Wang; Limei Yin; Zhuoran Yao; Ruizhan Tong; Jianxin Xue; You Lu
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

Review 2.  Current Advances in RNA Therapeutics for Human Diseases.

Authors:  Hannah Zogg; Rajan Singh; Seungil Ro
Journal:  Int J Mol Sci       Date:  2022-03-01       Impact factor: 5.923

Review 3.  Targeting HDAC6 to Overcome Autophagy-Promoted Anti-Cancer Drug Resistance.

Authors:  Hyein Jo; Kyeonghee Shim; Dooil Jeoung
Journal:  Int J Mol Sci       Date:  2022-08-24       Impact factor: 6.208

4.  Effect Evaluation of Bronchial Artery Embolization for Hemoptysis of Lung Cancer and Changes in Serum Tumor Markers and miR-34 Levels.

Authors:  Yan Huang; Hongxiang Liang; Zhiyong Yang; Hedai Liu; Judi Xu; Ying Huang; Qian Huang; Guoying Ni; Yufeng Ni
Journal:  Contrast Media Mol Imaging       Date:  2022-08-16       Impact factor: 3.009

5.  MiR-34b/c play a role in early sex differentiation of Amur sturgeon, Acipenser schrenckii.

Authors:  Xiujuan Zhang; Wenhua Wu; Jiabin Zhou; Linmiao Li; Haiying Jiang; Jinping Chen
Journal:  Front Zool       Date:  2022-09-26       Impact factor: 3.300

6.  MicroRNA-506 has a suppressive effect on the tumorigenesis of nonsmall-cell lung cancer by regulating tubby-like protein 3.

Authors:  Zhan-Hua Li; Ji-Hong Zhou; Si-Ning Chen; Ling Pan; Yuan Feng; Mei-Qun Luo; Rui-Xiang Li; Gui-Li Sun
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.